# Convalescent Plasma for Treatment of COVID-19

> **NCT04649879** · PHASE2,PHASE3 · COMPLETED · sponsor: **Joakim Dillner** · enrollment: 59 (actual)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 convalescent plasma
- **OTHER:** Standard of care

## Key facts

- **NCT ID:** NCT04649879
- **Lead sponsor:** Joakim Dillner
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-12-03
- **Primary completion:** 2022-01-26
- **Final completion:** 2022-01-26
- **Target enrollment:** 59 (ACTUAL)
- **Last updated:** 2022-02-09

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04649879

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04649879, "Convalescent Plasma for Treatment of COVID-19". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04649879. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*